Omega-3 ethylester concentrate

Drug Profile

Omega-3 ethylester concentrate

Alternative Names: Esapent; Eskim; Lotriga; Lovaza; Omacor; Seacor; TAK-085

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pronova Biocare
  • Developer Ferrer; GlaxoSmithKline; Kuhnil Pharmaceutical Company; Pronova BioPharma; Takeda
  • Class Antihyperlipidaemics; Omega 3 fatty acids
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors; Fatty acid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertriglyceridaemia; Postmyocardial infarction
  • Phase III Cardiovascular disorders
  • No development reported Heart failure; Hyperlipidaemia
  • Discontinued Atrial fibrillation; IgA nephropathy

Most Recent Events

  • 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
  • 19 Jul 2016 Takeda plans the exploratory LOTUS clinical trial for Hyperlipidaemia (Adjunctive treatment) in Japan (PO) (NCT02839902)
  • 05 Mar 2015 No recent reports on development identified - Preregistration for Heart failure in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top